KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $955.0 million.

  • Royalty Pharma's Cash & Current Investments fell 435.71% to $955.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $955.0 million, marking a year-over-year decrease of 435.71%. This contributed to the annual value of $987.2 million for FY2024, which is 9931.48% up from last year.
  • Royalty Pharma's Cash & Current Investments amounted to $955.0 million in Q3 2025, which was down 435.71% from $645.1 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash & Current Investments ranged from a high of $2.5 billion in Q2 2022 and a low of $495.3 million during Q4 2023
  • Its 5-year average for Cash & Current Investments is $1.4 billion, with a median of $1.2 billion in 2021.
  • As far as peak fluctuations go, Royalty Pharma's Cash & Current Investments surged by 97620.61% in 2021, and later plummeted by 7106.92% in 2023.
  • Over the past 5 years, Royalty Pharma's Cash & Current Investments (Quarter) stood at $1.6 billion in 2021, then grew by 6.53% to $1.7 billion in 2022, then tumbled by 71.07% to $495.3 million in 2023, then skyrocketed by 99.31% to $987.2 million in 2024, then dropped by 3.26% to $955.0 million in 2025.
  • Its Cash & Current Investments stands at $955.0 million for Q3 2025, versus $645.1 million for Q2 2025 and $1.1 billion for Q1 2025.